Skip to Content

Notice

Bulk Manufacturer of Controlled Substances Application: Noramco, Inc.

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

ACTION:

Notice of application.

DATES:

Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before March 20, 2017.

ADDRESSES:

Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152.

End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

The Attorney General has delegated her authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (“Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.33(a), this is notice that on July 12, 2016, Noramco, Inc., 500 Swedes Landing Road, Wilmington, Delaware 19801-4417 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Controlled substanceDrug codeSchedule
Marihuana7360I
Codeine-N-oxide9053I
Dihydromorphine9145I
Hydromorphinol9301I
Morphine-N-oxide9307I
Amphetamine1100II
Methylphenidate1724II
Phenylacetone8501II
Codeine9050II
Dihydrocodeine9120II
Oxycodone9143II
Hydromorphone9150II
Hydrocodone9193II
Morphine9300II
Oripavine9330II
Thebaine9333II
Opium extracts9610II
Opium fluid extract9620II
Opium tincture9630II
Opium, powdered9639II
Opium, granulated9640II
Oxymorphone9652II
Noroxymorphone9668II
Tapentadol9780II

The company plans to manufacture the above-listed controlled substances in bulk for distribution to its customers. In reference to drug code 7360, the company plans to manufacture a synthetic version of cannabidiol in bulk for sale to its customers, who are final dosage form manufacturers. No other activity for this drug code is authorized for this registration.

Start Signature

Dated: January 11, 2017.

Louis J. Milione,

Assistant Administrator.

End Signature End Supplemental Information

[FR Doc. 2017-01103 Filed 1-18-17; 8:45 am]

BILLING CODE 4410-09-P